Clinical trial Recruiting at 1 site Observational Ages 18 to 80

Assessing adrenal function in patients with Addison's disease

Official title: Residual Adrenal Function in Addison's Disease

Run by Istituto Auxologico Italiano · NCT06309498 · Data updated 2026-11-12

This study is testing whether measuring a specific hormone can help doctors understand how well the adrenal glands are working in people with Addison's disease and if that can improve their treatment and quality of life.

Quick facts

Study typeObservational
Ages18 Years to 80 Years
SexAll
Enrollment50 (estimated)
SponsorIstituto Auxologico Italiano
Academic / other
Locations1 site (Milan)
StatusRecruiting
StartedJanuary 1, 2023
Main results expectedDecember 30, 2027
Study endsDecember 31, 2027
Registry record updatedNovember 10, 2026
Trial IDNCT06309498 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are individuals diagnosed with autoimmune Addison's disease who can provide informed consent.

Probably not a fit

Patients currently taking drugs that affect the immune system or steroids other than hydrocortisone or cortisone acetate may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the role of 11-deoxycortisol as a surrogate marker for residual adrenal function in patients with autoimmune Addison's disease. It will involve measuring 11-deoxycortisol levels in recruited patients to determine if any residual endogenous corticosteroid production exists. The study seeks to understand the clinical significance of residual adrenal function, which may impact treatment needs and overall quality of life for patients. By identifying patients with residual function, the study could help tailor hormone replacement therapy more effectively.

Why it matters

Potential benefit: If successful, this study could lead to more personalized treatment plans for patients with Addison's disease, potentially reducing the need for hormone replacement therapy.

How similar studies have gone: While some studies have indicated the presence of residual adrenal function in a subset of Addison's patients, this specific approach using 11-deoxycortisol as a marker is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Autoimmune Addison's disease
* Informed consent

Exclusion Criteria:

\- Drugs affecting immune system or steroids other than hydrocortisone or cortisone acetate

Where it's running

  • Istituto Auxologico Italiano
    Milan, Italy
    Recruiting

Study contacts

  • Principal investigator: Valentina Morelli, PHD — Istituto Auxologico Italiano
  • Study coordinator: Valentina Morelli, PhD
  • Email: v.morelli@auxologico.it
  • Phone: 02619112547

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.